Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEBT-908 plus chemotherapy in MRD-positive MEF2D-rearranged / Pre-B BCP-ALL in complete remission
ChiCTR2600118827Phase 4Not yet recruiting
- Sponsor
- Ruijin Hospital
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ifupinostat in acute lymphoblastic leukemia (ALL), sponsored by Ruijin Hospital. Primary endpoint: MRD negativity rate. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
ifupinostat
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on ChiCTR2600118827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600118827.